BONE BIOLOGICS CORP (BBLG)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.32-6.74%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · BBLG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
BBLG — legal / regulatory event — Notice
Dated 2026-09-16
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 10, 2026, Bone Biologics Corporation (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a min…
Why it matters: The July financing brought in about $3.0 million. Management tied that cash to the study and key work through Q2 2027.
Worry ifA company filing says cash can fund operations through June 30, 2027, with no new financing before then.
Less concerning ifA filing reports a new share sale or says cash will not last through Q2 2027.
Why it matters: Nasdaq said BBLG failed its minimum bid-price rule. Keeping its listing depends on fixing that issue.
Worry ifA Nasdaq notice or company filing says BBLG met Listing Rule 5550(a)(2) by its cure deadline.
Less concerning ifNasdaq says BBLG failed to regain compliance by the deadline or will be delisted.
Why it matters: A longer validated shelf life may give the team more room to make and store NB1 supplies. The latest reported result was 29 months.
Supportive ifThe company reports a validated rhNELL-1 shelf life above 29 months.
Worry ifThe company reports that shelf life remains at 29 months or less, or that the 29-month result was not validated.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$245 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $678 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,466 loss on $10,000 · 84.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.